U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C13H17N5O8S2
Molecular Weight 435.433
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of AZTREONAM

SMILES

C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O

InChI

InChIKey=WZPBZJONDBGPKJ-VEHQQRBSSA-N
InChI=1S/C13H17N5O8S2/c1-5-7(10(20)18(5)28(23,24)25)16-9(19)8(6-4-27-12(14)15-6)17-26-13(2,3)11(21)22/h4-5,7H,1-3H3,(H2,14,15)(H,16,19)(H,21,22)(H,23,24,25)/b17-8-/t5-,7-/m0/s1

HIDE SMILES / InChI
Molecular Formula C13H17N5O8S2
Molecular Weight 435.433
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 1
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050580s040,050632s013lbl.pdf https://www.ncbi.nlm.nih.gov/pubmed/27334663

Aztreonam is the first monocyclic beta-lactam antibiotic (monobactam) originally isolated from Chromobacterium violaceum. Aztreonam has a high affinity for the protein-binding protein 3 (PBP-3) of aerobic gram-negative bacteria. Most of these organisms are inhibited and killed at low concentrations of the drug. Aztreonam must be administered as an intravenous or intramuscular injection (AZACTAM®), or inhaled (CAYSTON®). Aztreonam for injection is indicated for the treatment of the following infections caused by susceptible gram-negative microorganisms: urinary tract, lower respiratory tract, skin and skin-structure, intra-abdominal and gynecologic infections as well as for septicemia. Aztreonam for inhalation solution is indicated to improve respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa.

CNS Activity

Originator

Squibb & Sons
9
Sources: ISBN-13: 978-1461413998

Approval Year

1986
107
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
 0.03 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8583
AZACTAM

Approved Use

Aztreonam for Injection is indicated for the treatment of infections caused by susceptible gram-negative microorganisms.

Launch Date

1986
Curative
Approved
8583
AZACTAM

Approved Use

Aztreonam for Injection is indicated for the treatment of infections caused by susceptible gram-negative microorganisms.

Launch Date

1986
Curative
Approved
8583
AZACTAM

Approved Use

Aztreonam for Injection is indicated for the treatment of infections caused by susceptible gram-negative microorganisms.

Launch Date

1986
Curative
Approved
8583
AZACTAM

Approved Use

Aztreonam for Injection is indicated for the treatment of infections caused by susceptible gram-negative microorganisms.

Launch Date

1986
Curative
Approved
8583
AZACTAM

Approved Use

Aztreonam for Injection is indicated for the treatment of infections caused by susceptible gram-negative microorganisms.

Launch Date

1986
Curative
Approved
8583
AZACTAM

Approved Use

Aztreonam for Injection is indicated for the treatment of infections caused by susceptible gram-negative microorganisms.

Launch Date

1986
Palliative
Approved
8583
CAYSTON

Approved Use

CAYSTON® is indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa.

Launch Date

2010
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
54 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050580s040,050632s013lbl.pdf
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
AZTREONAM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
90 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050580s040,050632s013lbl.pdf
1 g single, intravenous
dose: 1 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
AZTREONAM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
204 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050580s040,050632s013lbl.pdf
2 g single, intravenous
dose: 2 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
AZTREONAM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
208 mg × h/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3710959
1 g 1 times / day steady-state, intravenous
dose: 1 g
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
AZTREONAM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.67 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3710959
1 g 1 times / day steady-state, intravenous
dose: 1 g
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
AZTREONAM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
44%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050580s040,050632s013lbl.pdf
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
AZTREONAM serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
30 mg/kg single, intravenous
Recommended
Dose: 30 mg/kg
Route: intravenous
Route: single
Dose: 30 mg/kg
Sources:
https://pubmed.ncbi.nlm.nih.gov/3774385/
unhealthy, 10 - 18 years
Health Status: unhealthy
Age Group: 10 - 18 years
Sex: unknown
Sources:
https://pubmed.ncbi.nlm.nih.gov/3774385/
Sources:
https://pubmed.ncbi.nlm.nih.gov/3774385/
1 g single, intramuscular
Recommended
Dose: 1 g
Route: intramuscular
Route: single
Dose: 1 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/3102347/
unhealthy, 18 - 75 years
Health Status: unhealthy
Age Group: 18 - 75 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/3102347/
Sources:
https://pubmed.ncbi.nlm.nih.gov/3102347/
1 g 3 times / day steady, intramuscular
Recommended
Dose: 1 g, 3 times / day
Route: intramuscular
Route: steady
Dose: 1 g, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050580s042lbl.pdf
unhealthy, children
Health Status: unhealthy
Age Group: children
Sex: unknown
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050580s042lbl.pdf
Other AEs: Rash, Diarrhea...
Other AEs:
Rash (4.3%)
Diarrhea (1.4%)
Fever (1%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050580s042lbl.pdf
1 g 3 times / day steady, intramuscular
Recommended
Dose: 1 g, 3 times / day
Route: intramuscular
Route: steady
Dose: 1 g, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050580s042lbl.pdf
unhealthy, children
Health Status: unhealthy
Age Group: children
Sex: unknown
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050580s042lbl.pdf
Other AEs: Pain, Erythema...
Other AEs:
Pain (12%)
Erythema (2.9%)
Induration (0.9%)
Phlebitis (2.1%)
Blood eosinophils increased (6.3%)
Increased platelets (3.6%)
Neutropenia (3.2%)
AST increased (3.8%)
ALT increased (6.5%)
Increased serum creatinine (5.8%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050580s042lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Fever 1%
1 g 3 times / day steady, intramuscular
Recommended
Dose: 1 g, 3 times / day
Route: intramuscular
Route: steady
Dose: 1 g, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050580s042lbl.pdf
unhealthy, children
Health Status: unhealthy
Age Group: children
Sex: unknown
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050580s042lbl.pdf
Diarrhea 1.4%
1 g 3 times / day steady, intramuscular
Recommended
Dose: 1 g, 3 times / day
Route: intramuscular
Route: steady
Dose: 1 g, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050580s042lbl.pdf
unhealthy, children
Health Status: unhealthy
Age Group: children
Sex: unknown
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050580s042lbl.pdf
Rash 4.3%
1 g 3 times / day steady, intramuscular
Recommended
Dose: 1 g, 3 times / day
Route: intramuscular
Route: steady
Dose: 1 g, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050580s042lbl.pdf
unhealthy, children
Health Status: unhealthy
Age Group: children
Sex: unknown
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050580s042lbl.pdf
Induration 0.9%
1 g 3 times / day steady, intramuscular
Recommended
Dose: 1 g, 3 times / day
Route: intramuscular
Route: steady
Dose: 1 g, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050580s042lbl.pdf
unhealthy, children
Health Status: unhealthy
Age Group: children
Sex: unknown
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050580s042lbl.pdf
Pain 12%
1 g 3 times / day steady, intramuscular
Recommended
Dose: 1 g, 3 times / day
Route: intramuscular
Route: steady
Dose: 1 g, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050580s042lbl.pdf
unhealthy, children
Health Status: unhealthy
Age Group: children
Sex: unknown
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050580s042lbl.pdf
Phlebitis 2.1%
1 g 3 times / day steady, intramuscular
Recommended
Dose: 1 g, 3 times / day
Route: intramuscular
Route: steady
Dose: 1 g, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050580s042lbl.pdf
unhealthy, children
Health Status: unhealthy
Age Group: children
Sex: unknown
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050580s042lbl.pdf
Erythema 2.9%
1 g 3 times / day steady, intramuscular
Recommended
Dose: 1 g, 3 times / day
Route: intramuscular
Route: steady
Dose: 1 g, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050580s042lbl.pdf
unhealthy, children
Health Status: unhealthy
Age Group: children
Sex: unknown
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050580s042lbl.pdf
Neutropenia 3.2%
1 g 3 times / day steady, intramuscular
Recommended
Dose: 1 g, 3 times / day
Route: intramuscular
Route: steady
Dose: 1 g, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050580s042lbl.pdf
unhealthy, children
Health Status: unhealthy
Age Group: children
Sex: unknown
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050580s042lbl.pdf
Increased platelets 3.6%
1 g 3 times / day steady, intramuscular
Recommended
Dose: 1 g, 3 times / day
Route: intramuscular
Route: steady
Dose: 1 g, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050580s042lbl.pdf
unhealthy, children
Health Status: unhealthy
Age Group: children
Sex: unknown
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050580s042lbl.pdf
AST increased 3.8%
1 g 3 times / day steady, intramuscular
Recommended
Dose: 1 g, 3 times / day
Route: intramuscular
Route: steady
Dose: 1 g, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050580s042lbl.pdf
unhealthy, children
Health Status: unhealthy
Age Group: children
Sex: unknown
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050580s042lbl.pdf
Increased serum creatinine 5.8%
1 g 3 times / day steady, intramuscular
Recommended
Dose: 1 g, 3 times / day
Route: intramuscular
Route: steady
Dose: 1 g, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050580s042lbl.pdf
unhealthy, children
Health Status: unhealthy
Age Group: children
Sex: unknown
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050580s042lbl.pdf
Blood eosinophils increased 6.3%
1 g 3 times / day steady, intramuscular
Recommended
Dose: 1 g, 3 times / day
Route: intramuscular
Route: steady
Dose: 1 g, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050580s042lbl.pdf
unhealthy, children
Health Status: unhealthy
Age Group: children
Sex: unknown
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050580s042lbl.pdf
ALT increased 6.5%
1 g 3 times / day steady, intramuscular
Recommended
Dose: 1 g, 3 times / day
Route: intramuscular
Route: steady
Dose: 1 g, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050580s042lbl.pdf
unhealthy, children
Health Status: unhealthy
Age Group: children
Sex: unknown
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050580s042lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP 450
20
CYP 450
32
CYP 450
12
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP 450
22
 unlikely
CYP 450
22
 unlikely
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP 450
32
 no
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:161680
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:161680
ChemicalBook
CB0386184
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0386184
eMolecules
17497503
https://www.emolecules.com/cgi-bin/more?vid=17497503
MolPort
MolPort-003-886-345
https://www.molport.com/shop/molecule-link/MolPort-003-886-345
Selleck Chemicals
Aztreonam(Azactam)
http://www.selleckchem.com/products/Aztreonam(Azactam).html
ZINC
ZINC000003830264
http://zinc15.docking.org/substances/ZINC000003830264
PubMed

PubMed

TitleDatePubMed
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005-06
Contribution of beta-lactamases to beta-lactam susceptibilities of susceptible and multidrug-resistant Mycobacterium tuberculosis clinical isolates.
1998-06
In-vitro activity of seventeen antimicrobial compounds against seven species of mycobacteria.
1988-12
Broth microdilution testing of susceptibilities to 30 antimicrobial agents of Mycobacterium avium strains from patients with acquired immune deficiency syndrome.
1987-10
Patents

Patents

20050032775
3
7262293
3

Sample Use Guides

In Vivo Use Guide
Curator's Comment: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050814s007lbl.pdf
Urinary tract infections (adults): 0.5-1 g 2-3 times/day. Moderately severe systemic infections (adults): 1-2 g 2-3 times/day. Severe systemic or life-threatening infections (adults): 2 g 3-4 times/day. Maximum recommended dose for adults is 8 g per day. Mild to moderate infections (pediatric patients): 30 mg/kg 3 times/day Moderate to severe infections (pediatric patients): 30 mg/kg 3-4 times/day. Maximum recommended dose for pediatric patients is 120 mg/kg/day. Inhalation solution: one dose (one single use vial and one ampule of diluent) 3 times a day for 28 days.
Route of Administration: Other
In Vitro Use Guide
In vitro, minimum inhibition concentration (MIC) values against almost all of the Enterobacteriaceae, Neisseria and Haemophilus strains were below 1 microgram per milliliter. MIC values against Pseudomonas aeruginosa were about 8 ug/ml.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:08:00 GMT 2025
Edited
by admin
on Mon Mar 31 18:08:00 GMT 2025
Record UNII
G2B4VE5GH8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AZACTAM
Preferred Name English
AZTREONAM
INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
AZTREONAM [JAN]
Common Name English
EMBLAVEO COMPONENT AZTREONAM
Brand Name English
AZTREON
Brand Name English
AZTREONAM [USP-RS]
Common Name English
SQ 26776
Code English
AZTREONAM [MI]
Common Name English
AZONAM
Brand Name English
AZTREONAM [USP MONOGRAPH]
Common Name English
AZTREONAM [VANDF]
Common Name English
AZTREONAM [USAN]
Common Name English
NEBACTAM
Brand Name English
Aztreonam [WHO-DD]
Common Name English
NSC-646279
Code English
PRIMBACTAM
Brand Name English
(Z)-2-[[[(2-Amino-4-thiazolyl)[[(2S,3S)-2-methyl-4-oxo-1-sulfo-3-azetidinyl]carbamoyl]methylene]amino]oxy]-2-methylpropionic acid
Systematic Name English
PROPANOIC ACID, 2-(((1-(2-AMINO-4-THIAZOLYL)-2-((2-METHYL-4-OXO-1-SULFO-3-AZETIDINYL)AMINO)-2-OXOETHYLIDENE)AMINO)OXY)-2-METHYL-, (2S-(2.ALPHA.,3.BETA.(Z)))-
Common Name English
AZTREONAM [MART.]
Common Name English
aztreonam [INN]
Common Name English
NSC-758913
Code English
SQ-26776
Code English
AZTREONAM [ORANGE BOOK]
Common Name English
Classification Tree Code System Code
NDF-RT N0000011311
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
NDF-RT N0000011311
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
LIVERTOX NBK548462
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
FDA ORPHAN DRUG 155002
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
NDF-RT N0000011311
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
NDF-RT N0000011311
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
NCI_THESAURUS C260
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
WHO-VATC QJ01DF01
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
NDF-RT N0000011311
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
WHO-ATC J01DF01
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
NDF-RT N0000011311
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
NDF-RT N0000011311
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
NDF-RT N0000011311
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
FDA ORPHAN DRUG 266208
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
NDF-RT N0000175493
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
NDF-RT N0000011311
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
Code System Code Type Description
ECHA (EC/EINECS)
278-839-9
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
PRIMARY
PUBCHEM
5742832
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
PRIMARY
MERCK INDEX
m2188
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
PRIMARY Merck Index
EVMPD
SUB05664MIG
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
PRIMARY
NCI_THESAURUS
C28845
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
PRIMARY
CHEBI
161680
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
PRIMARY
ChEMBL
CHEMBL3545256
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
PRIMARY
FDA UNII
G2B4VE5GH8
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
PRIMARY
LACTMED
Aztreonam
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
PRIMARY
CAS
78110-38-0
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
PRIMARY
NSC
646279
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
PRIMARY
DAILYMED
G2B4VE5GH8
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
PRIMARY
EPA CompTox
DTXSID0022640
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
PRIMARY
DRUG BANK
DB00355
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
PRIMARY
SMS_ID
100000091595
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
PRIMARY
DRUG CENTRAL
279
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
PRIMARY
MESH
D001398
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
PRIMARY
RXCUI
1272
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
PRIMARY RxNorm
WIKIPEDIA
AZTREONAM
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
PRIMARY
INN
5159
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
PRIMARY
NSC
758913
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
PRIMARY
RS_ITEM_NUM
1046205
Created by admin on Mon Mar 31 18:08:00 GMT 2025 , Edited by admin on Mon Mar 31 18:08:00 GMT 2025
PRIMARY
Related Record Type Details
PSEUDOMONAS AERUGINOSA
TARGET ORGANISM->INHIBITOR
Indicated for the suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 6 years and older.
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Structure of AZTREONAM LYSINE
SALT/SOLVATE -> PARENT
Structure of AZTREONAM
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Related Record Type Details
Structure of SQ-26992
METABOLITE INACTIVE -> PARENT
Related Record Type Details
Structure of DESULFATED AZTREONAM
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of SQ-26992
IMPURITY -> PARENT
Open-ring aztreonam and open-ring desulfated aztreonam coelute. The limit is for the sum of these two impurities (1.0 WEUGHT PERCENT)
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of SQ-28429
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of AZTREONAM ETHYL ESTER
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of OPEN-RING DESULFATED AZTREONAM
IMPURITY -> PARENT
Open-ring aztreonam and open-ring desulfated aztreonam coelute. The limit is for the sum of these two impurities (1.0 WEIGHT PERCENT)
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
Structure of AZTREONAM
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Cmax PHARMACOKINETIC Amount Administered
PHARMACOKINETIC
Time of measurement
PHARMACOKINETIC
Dosage form
PHARMACOKINETIC
Method of administration
PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966